Search This Blog

Monday, April 1, 2019

Salix Pharmaceuticals enters license agreement with University Of California

Salix Pharmaceuticals announced its affiliate has entered into a license agreement with the University of California via UCLA’s Technology Development Group for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and various other gastrointestinal and liver diseases.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.